Hikma Pharmaceuticals Plc (LON:HIK) is scheduled to be releasing its earnings data before the market opens on Thursday, August 17th.

Hikma Pharmaceuticals Plc (LON:HIK) opened at 1308.00 on Thursday. Hikma Pharmaceuticals Plc has a 1-year low of GBX 1,294.50 and a 1-year high of GBX 2,354.00. The company has a 50-day moving average price of GBX 1,435.42 and a 200-day moving average price of GBX 1,784.66. The firm’s market capitalization is GBX 3.15 billion.

A number of research analysts have recently commented on HIK shares. HSBC Holdings plc reaffirmed a “reduce” rating and set a GBX 1,800 ($23.44) price objective on shares of Hikma Pharmaceuticals Plc in a research report on Friday, May 5th. Numis Securities Ltd reaffirmed a “buy” rating and set a GBX 2,350 ($30.60) price objective on shares of Hikma Pharmaceuticals Plc in a research report on Thursday, May 11th. J P Morgan Chase & Co cut their price objective on shares of Hikma Pharmaceuticals Plc from GBX 2,400 ($31.25) to GBX 1,800 ($23.44) and set a “neutral” rating for the company in a research report on Friday, May 12th. Jefferies Group LLC lowered shares of Hikma Pharmaceuticals Plc to an “underperform” rating and cut their price objective for the company from GBX 2,162 ($28.15) to GBX 1,450 ($18.88) in a research report on Wednesday, May 17th. Finally, Citigroup Inc. reaffirmed a “neutral” rating and set a GBX 1,550 ($20.18) price objective on shares of Hikma Pharmaceuticals Plc in a research report on Wednesday, June 28th. Two analysts have rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the company. Hikma Pharmaceuticals Plc currently has a consensus rating of “Hold” and a consensus price target of GBX 1,936.10 ($25.21).

COPYRIGHT VIOLATION NOTICE: This report was first reported by Daily Political and is the property of of Daily Political. If you are accessing this report on another publication, it was illegally stolen and republished in violation of US & international copyright and trademark legislation. The original version of this report can be accessed at https://www.dailypolitical.com/2017/08/09/hikma-pharmaceuticals-plc-hik-scheduled-to-post-earnings-on-thursday.html.

About Hikma Pharmaceuticals Plc

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.

Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with MarketBeat.com's FREE daily email newsletter.